■ MANTIS

CDMO, Small Molecule
& Bioprocess Intelligence
Updated 28 July 2026  ·  75 companies monitored
1,351
Signals
30 days
75
Companies
tracked
268
Predictions
logged
Leading narrative GLP-1 Manufacturing Capacity Rolling 7 days
Leading tech themeSmall MoleculePatent & publication signals · 30 days
Story of the week
↗ Accelerating GLP-1 Manufacturing Capacity
1187signals this week · 63companies active
Signal of the week
FDA Action ●●●●○○○○  4/10
Drug Approval: RETEVMO (manufactured by Eli Lilly)
Narrative tracker — signals · rolling 7 days
01GLP-1 Manufacturing Capacity1187
02Biosimilar Market Expansion491
03Cell & Gene Therapy Manufacturing380
04India Generics & API Expansion360
05Sector Consolidation & M&A340
06Manufacturing Capacity Expansion218
07FDA / Regulatory Pressure165
08ADC Outsourcing Wave165
09Generic & Biosimilar Market Dynamics82
10Next-Gen Manufacturing Technology80
Narrative momentum — rolling 30 days
Narrative momentum — 30 days

Each line tracks one sector narrative — 7-day rolling average of signal volume and cross-source breadth, updated daily.

This week in pharma manufacturing
📰Fierce Pharma Asia—Trump’s generic drug tariffs; Samsung Bio’s $1.8B acquisition; An unusual IPOSamsung Biologicsfiercepharma.comM&A 📰Cellares and Papillon partner for PPL-001 manufacturing automationCellarespharmaceutical-technology.comPartnership 📰Samsung Biologics: geographic diversification is a sound business decisionSamsung Biologicspharmaceutical-technology.com
Deal intelligence — partnerships & capacity moves
🤝Samsung Biologics spreads wings with proposed $1.8B acquisition of Swiss CDMO PolyPeptideSamsung Biologics6 🤝Fierce Pharma Asia—Trump’s generic drug tariffs; Samsung Bio’s $1.8B acquisition; An unusual IPOSamsung Biologics6 🤝Cellares and Papillon partner for PPL-001 manufacturing automationCellares4 🤝Samsung Biologics to acquire PolyPeptide in $1.81bn cash dealSamsung Biologics8
Demand drivers — pharma pipeline signals Pharma pipeline signals
📈Roche defends 6B franc Vabysmo peak sales target despite another quarterly missRoche4 📈Bristol Myers, NVIDIA join forces to build life science’s ‘most powerful’ AI factoryBristol Myers Squibb2 📈FDA grants priority review to Roche’s Gazyva/Gazyvaro for pMNRoche2 📈Novo secures European approval for oral Wegovy to extend lead over LillyEli Lilly2 📈Novo sues Lilly after alleged misleading and false advertising campaignEli Lilly2
How it works
01
Collect
Signals ingested daily across clinical trials, FDA and EMA regulatory filings, scientific publications, SEC disclosures, hiring patterns, and industry news. Each signal is scored and classified by therapy area and signal type.
02
Converge
When multiple independent sources flag the same company within a rolling window, a convergence alert fires. Cross-source agreement is the signal — a single news article is noise; a clinical filing, a hiring surge, and a regulatory action on the same company are not.
03
Synthesise
A weekly synthesis covers what moved, what it implies, and where to look next. Predictions are made explicitly and logged — then scored as outcomes become known. Company-level intelligence briefs covering signal momentum, risk flags, and capability profiles are available on request.
Signal sources — rolling 30 days
News889
Clinical Trials225
Science140
FDA59
SEC Filings16
Hiring13
Patent Cliff9

Mantis runs continuously — ingesting signals, scoring convergence, and tracking whether its predictions come true. It does not summarise headlines. It identifies when independent data sources start moving in the same direction on the same company, and asks what that combination of evidence implies. Built for the pharma advisor or investor who needs to know which CDMOs are moving before the headlines explain why.

CDMO selection · competitive intelligence · strategic advice
Intelligence briefings and company assessments available on request.
[email protected] →
[email protected] © 2026 Mantis Intelligence.

Mantis Intelligence is not authorised or regulated by the Financial Conduct Authority or any other financial regulator. Content is produced by automated systems and artificial intelligence for information and research purposes only. Nothing on this site constitutes investment advice, a personal recommendation, or a solicitation. Past signal patterns are not predictive of future events or outcomes.

Signals are sourced from public regulatory filings (FDA, EMA, SEC EDGAR), clinical trial registries, scientific publication databases, and publicly available news feeds. This site sets no cookies and collects no personal data.